TY - JOUR
T1 - Does Acute Propranolol Treatment Prevent Posttraumatic Stress Disorder, Anxiety, and Depression in Children with Burns?
AU - Rosenberg, Laura
AU - Rosenberg, Marta
AU - Sharp, Sherri
AU - Thomas, Christopher R.
AU - Humphries, Helen F.
AU - Holzer, Charles E.
AU - Herndon, David N.
AU - Meyer, Walter J.
N1 - Funding Information:
Permission for this study was obtained from the Institutional Review Board of the University of Texas Medical Branch-Galveston. This was a Shrine funded project with additional support from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR), formerly National Institute on Disability and Rehabilitation Research (NIDRR), because some of the children were invited to participate when they attended their scheduled NIDILRR appointments at this burn center.
Funding Information:
This research was supported by a Shrine Grant 71000. The contents of this article were partially supported by a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR H133A970019, H133A020102, H133A070026). The current NIDILRR grant number is 90DPBU0003. NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this article do not necessarily represent the policy of NIDILRR, ACL, or HHS, and you should not assume endorsement by the federal government. The authors would like to thank the children and families who participated in this study.
Publisher Copyright:
© Copyright 2018, Mary Ann Liebert, Inc.
PY - 2018/3
Y1 - 2018/3
N2 - Objective: This study examined whether acute propranolol treatment prevented posttraumatic stress disorder (PTSD), anxiety, and depression in children hospitalized in the pediatric intensive care unit for large burns. We hypothesized that the prevalence of PTSD, anxiety, and depression would be significantly less in the propranolol than nonpropranolol groups. Methods: Children who had previously participated in a randomized controlled clinical trial of acute propranolol and nonpropranolol controls were invited to participate in long-term follow-up interviews. Eligible participants from 1997 to 2008 were identified from the electronic medical records, and data were collected in 2010-2011. Measures included the Missouri Assessment of Genetics Interview for Children to assess lifetime PTSD, Revised Children's Manifest Anxiety Scale to assess anxiety, and two depression inventories Children's Depression Inventory and Beck Depression Inventory-II. Results: Of 202 participants, 89 were in the propranolol group and 113 were nonpropranolol controls. Children were an average of 7 years postburn. The average total body surface area burned was 56.4 + 15.1% (range = 24%-99%). The mean dose of propranolol was 3.64 ± 3.19 mg/kg per day (range = 0.36-12.12). The duration of propranolol inpatient treatment days varied, mean days 26.5 ± 19.8. The prevalence of lifetime PTSD in the propranolol group was 3.5% and controls 7.2%, but this difference was not statistically significant. We controlled for administration of pain medications, anxiolytics, and antidepressants overall and no significant differences were detected in the rates of PTSD, anxiety, or depression. Conclusions: The prevalence of PTSD, anxiety, and depression was similar in children who received propranolol acutely and those who did not. This may be influenced by the standard of care that all children received timely pharmacotherapy for pain and anxiety management and psychotherapy beginning in their acute phase of treatment.
AB - Objective: This study examined whether acute propranolol treatment prevented posttraumatic stress disorder (PTSD), anxiety, and depression in children hospitalized in the pediatric intensive care unit for large burns. We hypothesized that the prevalence of PTSD, anxiety, and depression would be significantly less in the propranolol than nonpropranolol groups. Methods: Children who had previously participated in a randomized controlled clinical trial of acute propranolol and nonpropranolol controls were invited to participate in long-term follow-up interviews. Eligible participants from 1997 to 2008 were identified from the electronic medical records, and data were collected in 2010-2011. Measures included the Missouri Assessment of Genetics Interview for Children to assess lifetime PTSD, Revised Children's Manifest Anxiety Scale to assess anxiety, and two depression inventories Children's Depression Inventory and Beck Depression Inventory-II. Results: Of 202 participants, 89 were in the propranolol group and 113 were nonpropranolol controls. Children were an average of 7 years postburn. The average total body surface area burned was 56.4 + 15.1% (range = 24%-99%). The mean dose of propranolol was 3.64 ± 3.19 mg/kg per day (range = 0.36-12.12). The duration of propranolol inpatient treatment days varied, mean days 26.5 ± 19.8. The prevalence of lifetime PTSD in the propranolol group was 3.5% and controls 7.2%, but this difference was not statistically significant. We controlled for administration of pain medications, anxiolytics, and antidepressants overall and no significant differences were detected in the rates of PTSD, anxiety, or depression. Conclusions: The prevalence of PTSD, anxiety, and depression was similar in children who received propranolol acutely and those who did not. This may be influenced by the standard of care that all children received timely pharmacotherapy for pain and anxiety management and psychotherapy beginning in their acute phase of treatment.
KW - anxiety
KW - burns
KW - children
KW - depression
KW - posttraumatic stress disorder
KW - propranolol
UR - http://www.scopus.com/inward/record.url?scp=85042881661&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042881661&partnerID=8YFLogxK
U2 - 10.1089/cap.2017.0073
DO - 10.1089/cap.2017.0073
M3 - Article
C2 - 29161523
AN - SCOPUS:85042881661
SN - 1044-5463
VL - 28
SP - 117
EP - 123
JO - Journal of Child and Adolescent Psychopharmacology
JF - Journal of Child and Adolescent Psychopharmacology
IS - 2
ER -